Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INCA033890
- Development stage
- Phase 1
- Lead developer
- Incyte
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
INCA033890 is an investigational, orally bioavailable small molecule inhibitor of cyclin-dependent kinase 2 (CDK2) developed by Incyte Corporation. CDK2 is a serine/threonine kinase that, when complexed with Cyclin E, regulates the G1/S phase transition and S-phase progression of the cell cycle. Dysregulation of the CDK2/Cyclin E pathway, often through CCNE1 amplification, is a known driver of oncogenesis and a mechanism of resistance to CDK4/6 inhibitors in various cancers, including breast, ovarian, and uterine malignancies. INCA033890 is designed to selectively inhibit CDK2, thereby inducing cell cycle arrest and inhibiting the proliferation of tumor cells that are dependent on CDK2 activity. It is currently being evaluated in Phase 1 clinical trials for the treatment of advanced or metastatic solid tumors.
Beyond the preview
Go deeper on INCA033890.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INCA033890.